StonvexLoading…
StonvexStonvexStonvexCore line items from ANGI's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $238.15M | $1.03B | $789.77M | $524.13M |
Operating Income | $-9.46M | $65.41M | $59.46M | $37.68M |
Net Income | $-8.98M | $43.83M | $36.61M | $26.00M |
EPS (Diluted) | $-0.22 | $0.94 | $0.77 | $0.53 |
Total Assets | $1.63B | $1.68B | $1.75B | $1.79B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $244.58M | $303.70M | $340.69M | $362.48M |
Free Cash Flow OCF − CapEx | $-33.63M | $45.47M | $34.12M | $29.18M |
Shares Outstanding | 40.15M | 46.45M | 47.74M | 49.06M |